Chlorhexidine Varnish

PreclinicalSmall molecule

KKhyber Medical University Peshawar

Chlorhexidine Varnish is one of 27 small molecule programs targeting Hyperplasia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperplasiaActive, not recruiting

HyperplasiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

37 competitors in Hyperplasia

#DrugCompanyPhaseTrials

Lialda

Takeda

Approved

1 2

Nolvadex

Megace

4 4

Propecia

Flomax

2 6

Vesicare

Astellas

Phase 3

1 7

Victoza

Novo Nordisk

Phase 3

1 8

Femara

Novartis

Phase 3

1 9

Ativan

BBausch Health Americas, Inc.

Phase 3

1 10

Gnrh Ant

Merck & Co.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hyperplasia1 trial

Clinical Efficacy of Chlorhexidine Varnish in Reducing Gingival Hyperplasia, Plaque Accumulation, and White Spot Lesions in Orthodontic Patients

Recruiting·KKhyber Medical University Peshawar·N/A·NCT07115784·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Chlorhexidine Varnish. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Chlorhexidine Varnish compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Chlorhexidine Varnish. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Khyber Medical University Peshawar company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKhyber Medical University Peshawar

Chlorhexidine Varnish

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hyperplasia1 trial

References

Drug Info

Quick Facts

Related News